



## Dicerna to Participate in Citi's 2018 Global Healthcare Conference

November 29, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 29, 2018-- [Dicerna Pharmaceuticals, Inc.](#) (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will host one-on-one investor meetings at Citi's 2018 Global Healthcare Conference at the Lotte New York Palace Hotel in New York on Thursday, December 6, 2018. An investor deck will be available that day, on the Investor & Media section of the Dicerna website at [www.dicerna.com](http://www.dicerna.com).

### About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Boehringer Ingelheim, Eli Lilly and Company, and Alexion Pharmaceuticals. For more information, please visit [www.dicerna.com](http://www.dicerna.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181129005144/en/>

Source: Dicerna Pharmaceuticals, Inc.

### Investor Contact:

Rx Communications Group  
Paula Schwartz, 917-322-2216  
[pschwartz@rxir.com](mailto:pschwartz@rxir.com)

### Media Contact:

SmithSolve  
Alex Van Rees, 973-442-1555 ext. 111  
[alex.vanrees@smithsolve.com](mailto:alex.vanrees@smithsolve.com)